nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—Ibuprofen—Melphalan—ovarian cancer	0.405	1	CrCrCtD
Naproxen—SLCO1A2—Chlorambucil—ovarian cancer	0.137	0.368	CbGbCtD
Naproxen—AKR1C3—Doxorubicin—ovarian cancer	0.128	0.344	CbGbCtD
Naproxen—UGT2B7—Epirubicin—ovarian cancer	0.075	0.202	CbGbCtD
Naproxen—CYP2C8—Paclitaxel—ovarian cancer	0.0187	0.0505	CbGbCtD
Naproxen—CYP2C9—Paclitaxel—ovarian cancer	0.0131	0.0352	CbGbCtD
Naproxen—PTGS2—ovarian follicle—ovarian cancer	0.00364	0.138	CbGeAlD
Naproxen—AKR1C3—Vincristine—Vinorelbine—ovarian cancer	0.00184	0.554	CbGdCrCtD
Naproxen—PTGS1—oviduct—ovarian cancer	0.00167	0.0637	CbGeAlD
Naproxen—AKR1C3—myometrium—ovarian cancer	0.00151	0.0576	CbGeAlD
Naproxen—AKR1C3—Vinblastine—Vinorelbine—ovarian cancer	0.00148	0.446	CbGdCrCtD
Naproxen—AKR1C3—uterine cervix—ovarian cancer	0.00118	0.0448	CbGeAlD
Naproxen—AKR1C3—decidua—ovarian cancer	0.00112	0.0427	CbGeAlD
Naproxen—AKR1C3—endometrium—ovarian cancer	0.00106	0.0405	CbGeAlD
Naproxen—AKR1C3—uterus—ovarian cancer	0.00098	0.0373	CbGeAlD
Naproxen—UGT2B7—female reproductive system—ovarian cancer	0.000956	0.0364	CbGeAlD
Naproxen—AKR1C3—bone marrow—ovarian cancer	0.000832	0.0317	CbGeAlD
Naproxen—AKR1C3—female gonad—ovarian cancer	0.000802	0.0305	CbGeAlD
Naproxen—AKR1C3—vagina—ovarian cancer	0.000797	0.0304	CbGeAlD
Naproxen—UGT2B7—testis—ovarian cancer	0.000771	0.0294	CbGeAlD
Naproxen—AKR1C3—testis—ovarian cancer	0.000711	0.0271	CbGeAlD
Naproxen—Indomethacin—CXCL8—ovarian cancer	0.000689	0.33	CrCbGaD
Naproxen—Ketoprofen—CXCL8—ovarian cancer	0.000551	0.264	CrCbGaD
Naproxen—Ibuprofen—CXCL8—ovarian cancer	0.000543	0.26	CrCbGaD
Naproxen—AKR1C3—lymph node—ovarian cancer	0.000515	0.0196	CbGeAlD
Naproxen—PTGS2—myometrium—ovarian cancer	0.000511	0.0195	CbGeAlD
Naproxen—PTGS2—embryo—ovarian cancer	0.000492	0.0187	CbGeAlD
Naproxen—CYP2C8—endometrium—ovarian cancer	0.000464	0.0177	CbGeAlD
Naproxen—SLCO1A2—testis—ovarian cancer	0.000444	0.0169	CbGeAlD
Naproxen—ALB—testis—ovarian cancer	0.000441	0.0168	CbGeAlD
Naproxen—PTGS1—epithelium—ovarian cancer	0.00042	0.016	CbGeAlD
Naproxen—PTGS1—uterine cervix—ovarian cancer	0.000416	0.0159	CbGeAlD
Naproxen—PTGS2—epithelium—ovarian cancer	0.000401	0.0153	CbGeAlD
Naproxen—PTGS2—uterine cervix—ovarian cancer	0.000398	0.0152	CbGeAlD
Naproxen—CYP2C8—female reproductive system—ovarian cancer	0.000384	0.0146	CbGeAlD
Naproxen—PTGS1—endometrium—ovarian cancer	0.000376	0.0143	CbGeAlD
Naproxen—PTGS2—endometrium—ovarian cancer	0.00036	0.0137	CbGeAlD
Naproxen—CYP2C8—vagina—ovarian cancer	0.000348	0.0132	CbGeAlD
Naproxen—PTGS1—uterus—ovarian cancer	0.000347	0.0132	CbGeAlD
Naproxen—CYP2C9—female reproductive system—ovarian cancer	0.000341	0.013	CbGeAlD
Naproxen—PTGS2—uterus—ovarian cancer	0.000331	0.0126	CbGeAlD
Naproxen—ALB—lymph node—ovarian cancer	0.00032	0.0122	CbGeAlD
Naproxen—PTGS1—female reproductive system—ovarian cancer	0.000312	0.0119	CbGeAlD
Naproxen—CYP2C8—testis—ovarian cancer	0.00031	0.0118	CbGeAlD
Naproxen—PTGS2—female reproductive system—ovarian cancer	0.000298	0.0114	CbGeAlD
Naproxen—PTGS1—female gonad—ovarian cancer	0.000284	0.0108	CbGeAlD
Naproxen—PTGS1—vagina—ovarian cancer	0.000282	0.0107	CbGeAlD
Naproxen—PTGS2—bone marrow—ovarian cancer	0.000281	0.0107	CbGeAlD
Naproxen—PTGS2—female gonad—ovarian cancer	0.000271	0.0103	CbGeAlD
Naproxen—PTGS2—vagina—ovarian cancer	0.000269	0.0103	CbGeAlD
Naproxen—PTGS1—testis—ovarian cancer	0.000252	0.00958	CbGeAlD
Naproxen—PTGS1—lymph node—ovarian cancer	0.000182	0.00695	CbGeAlD
Naproxen—PTGS2—lymph node—ovarian cancer	0.000174	0.00664	CbGeAlD
Naproxen—Indomethacin—ABCB1—ovarian cancer	0.000171	0.0818	CrCbGaD
Naproxen—Ibuprofen—ABCB1—ovarian cancer	0.000135	0.0644	CrCbGaD
Naproxen—Decreased appetite—Paclitaxel—ovarian cancer	7.18e-05	0.000433	CcSEcCtD
Naproxen—Dry mouth—Docetaxel—ovarian cancer	7.14e-05	0.000431	CcSEcCtD
Naproxen—Gastrointestinal disorder—Paclitaxel—ovarian cancer	7.13e-05	0.000431	CcSEcCtD
Naproxen—Fatigue—Paclitaxel—ovarian cancer	7.12e-05	0.00043	CcSEcCtD
Naproxen—Sweating—Epirubicin—ovarian cancer	7.1e-05	0.000429	CcSEcCtD
Naproxen—Pollakiuria—Doxorubicin—ovarian cancer	7.1e-05	0.000429	CcSEcCtD
Naproxen—Pain—Paclitaxel—ovarian cancer	7.06e-05	0.000426	CcSEcCtD
Naproxen—Constipation—Paclitaxel—ovarian cancer	7.06e-05	0.000426	CcSEcCtD
Naproxen—Haematuria—Epirubicin—ovarian cancer	7.06e-05	0.000426	CcSEcCtD
Naproxen—Confusional state—Docetaxel—ovarian cancer	7.06e-05	0.000426	CcSEcCtD
Naproxen—Photosensitivity reaction—Doxorubicin—ovarian cancer	7.01e-05	0.000423	CcSEcCtD
Naproxen—Hepatobiliary disease—Epirubicin—ovarian cancer	7e-05	0.000423	CcSEcCtD
Naproxen—Anaphylactic shock—Docetaxel—ovarian cancer	7e-05	0.000423	CcSEcCtD
Naproxen—Oedema—Docetaxel—ovarian cancer	7e-05	0.000423	CcSEcCtD
Naproxen—Epistaxis—Epirubicin—ovarian cancer	6.98e-05	0.000422	CcSEcCtD
Naproxen—Infection—Docetaxel—ovarian cancer	6.95e-05	0.00042	CcSEcCtD
Naproxen—Weight decreased—Doxorubicin—ovarian cancer	6.95e-05	0.00042	CcSEcCtD
Naproxen—Sinusitis—Epirubicin—ovarian cancer	6.94e-05	0.000419	CcSEcCtD
Naproxen—Hyperglycaemia—Doxorubicin—ovarian cancer	6.93e-05	0.000418	CcSEcCtD
Naproxen—Agranulocytosis—Epirubicin—ovarian cancer	6.91e-05	0.000417	CcSEcCtD
Naproxen—Pneumonia—Doxorubicin—ovarian cancer	6.89e-05	0.000416	CcSEcCtD
Naproxen—Shock—Docetaxel—ovarian cancer	6.89e-05	0.000416	CcSEcCtD
Naproxen—Nervous system disorder—Docetaxel—ovarian cancer	6.86e-05	0.000415	CcSEcCtD
Naproxen—Thrombocytopenia—Docetaxel—ovarian cancer	6.85e-05	0.000414	CcSEcCtD
Naproxen—Drowsiness—Doxorubicin—ovarian cancer	6.85e-05	0.000414	CcSEcCtD
Naproxen—Tachycardia—Docetaxel—ovarian cancer	6.83e-05	0.000413	CcSEcCtD
Naproxen—Feeling abnormal—Paclitaxel—ovarian cancer	6.8e-05	0.000411	CcSEcCtD
Naproxen—Skin disorder—Docetaxel—ovarian cancer	6.8e-05	0.000411	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	6.79e-05	0.00041	CcSEcCtD
Naproxen—Gastrointestinal pain—Paclitaxel—ovarian cancer	6.75e-05	0.000408	CcSEcCtD
Naproxen—Renal failure—Doxorubicin—ovarian cancer	6.73e-05	0.000407	CcSEcCtD
Naproxen—Neuropathy peripheral—Doxorubicin—ovarian cancer	6.71e-05	0.000405	CcSEcCtD
Naproxen—Haemoglobin—Epirubicin—ovarian cancer	6.68e-05	0.000403	CcSEcCtD
Naproxen—Stomatitis—Doxorubicin—ovarian cancer	6.68e-05	0.000403	CcSEcCtD
Naproxen—Jaundice—Doxorubicin—ovarian cancer	6.68e-05	0.000403	CcSEcCtD
Naproxen—Anorexia—Docetaxel—ovarian cancer	6.67e-05	0.000403	CcSEcCtD
Naproxen—Rhinitis—Epirubicin—ovarian cancer	6.66e-05	0.000402	CcSEcCtD
Naproxen—Urinary tract infection—Doxorubicin—ovarian cancer	6.66e-05	0.000402	CcSEcCtD
Naproxen—Conjunctivitis—Doxorubicin—ovarian cancer	6.66e-05	0.000402	CcSEcCtD
Naproxen—Haemorrhage—Epirubicin—ovarian cancer	6.64e-05	0.000401	CcSEcCtD
Naproxen—Hepatitis—Epirubicin—ovarian cancer	6.64e-05	0.000401	CcSEcCtD
Naproxen—Pharyngitis—Epirubicin—ovarian cancer	6.59e-05	0.000398	CcSEcCtD
Naproxen—Sweating—Doxorubicin—ovarian cancer	6.57e-05	0.000397	CcSEcCtD
Naproxen—Urinary tract disorder—Epirubicin—ovarian cancer	6.56e-05	0.000396	CcSEcCtD
Naproxen—Urticaria—Paclitaxel—ovarian cancer	6.56e-05	0.000396	CcSEcCtD
Naproxen—Oedema peripheral—Epirubicin—ovarian cancer	6.55e-05	0.000395	CcSEcCtD
Naproxen—Hypotension—Docetaxel—ovarian cancer	6.54e-05	0.000395	CcSEcCtD
Naproxen—Haematuria—Doxorubicin—ovarian cancer	6.53e-05	0.000394	CcSEcCtD
Naproxen—Connective tissue disorder—Epirubicin—ovarian cancer	6.53e-05	0.000394	CcSEcCtD
Naproxen—Abdominal pain—Paclitaxel—ovarian cancer	6.53e-05	0.000394	CcSEcCtD
Naproxen—Body temperature increased—Paclitaxel—ovarian cancer	6.53e-05	0.000394	CcSEcCtD
Naproxen—Urethral disorder—Epirubicin—ovarian cancer	6.51e-05	0.000393	CcSEcCtD
Naproxen—Hepatobiliary disease—Doxorubicin—ovarian cancer	6.48e-05	0.000391	CcSEcCtD
Naproxen—Epistaxis—Doxorubicin—ovarian cancer	6.46e-05	0.00039	CcSEcCtD
Naproxen—Sinusitis—Doxorubicin—ovarian cancer	6.43e-05	0.000388	CcSEcCtD
Naproxen—Visual impairment—Epirubicin—ovarian cancer	6.4e-05	0.000387	CcSEcCtD
Naproxen—Agranulocytosis—Doxorubicin—ovarian cancer	6.39e-05	0.000386	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Docetaxel—ovarian cancer	6.38e-05	0.000385	CcSEcCtD
Naproxen—Insomnia—Docetaxel—ovarian cancer	6.33e-05	0.000382	CcSEcCtD
Naproxen—Paraesthesia—Docetaxel—ovarian cancer	6.28e-05	0.00038	CcSEcCtD
Naproxen—Erythema multiforme—Epirubicin—ovarian cancer	6.28e-05	0.000379	CcSEcCtD
Naproxen—Dyspnoea—Docetaxel—ovarian cancer	6.24e-05	0.000377	CcSEcCtD
Naproxen—Somnolence—Docetaxel—ovarian cancer	6.22e-05	0.000376	CcSEcCtD
Naproxen—Eye disorder—Epirubicin—ovarian cancer	6.21e-05	0.000375	CcSEcCtD
Naproxen—Tinnitus—Epirubicin—ovarian cancer	6.2e-05	0.000374	CcSEcCtD
Naproxen—Haemoglobin—Doxorubicin—ovarian cancer	6.18e-05	0.000373	CcSEcCtD
Naproxen—Cardiac disorder—Epirubicin—ovarian cancer	6.17e-05	0.000372	CcSEcCtD
Naproxen—Rhinitis—Doxorubicin—ovarian cancer	6.16e-05	0.000372	CcSEcCtD
Naproxen—Dyspepsia—Docetaxel—ovarian cancer	6.16e-05	0.000372	CcSEcCtD
Naproxen—Haemorrhage—Doxorubicin—ovarian cancer	6.15e-05	0.000371	CcSEcCtD
Naproxen—Hepatitis—Doxorubicin—ovarian cancer	6.15e-05	0.000371	CcSEcCtD
Naproxen—Pharyngitis—Doxorubicin—ovarian cancer	6.1e-05	0.000369	CcSEcCtD
Naproxen—Decreased appetite—Docetaxel—ovarian cancer	6.08e-05	0.000367	CcSEcCtD
Naproxen—Hypersensitivity—Paclitaxel—ovarian cancer	6.08e-05	0.000367	CcSEcCtD
Naproxen—Urinary tract disorder—Doxorubicin—ovarian cancer	6.07e-05	0.000367	CcSEcCtD
Naproxen—Oedema peripheral—Doxorubicin—ovarian cancer	6.06e-05	0.000366	CcSEcCtD
Naproxen—Gastrointestinal disorder—Docetaxel—ovarian cancer	6.04e-05	0.000365	CcSEcCtD
Naproxen—Connective tissue disorder—Doxorubicin—ovarian cancer	6.04e-05	0.000365	CcSEcCtD
Naproxen—Fatigue—Docetaxel—ovarian cancer	6.03e-05	0.000364	CcSEcCtD
Naproxen—Angiopathy—Epirubicin—ovarian cancer	6.03e-05	0.000364	CcSEcCtD
Naproxen—Urethral disorder—Doxorubicin—ovarian cancer	6.03e-05	0.000364	CcSEcCtD
Naproxen—Immune system disorder—Epirubicin—ovarian cancer	6e-05	0.000362	CcSEcCtD
Naproxen—Mediastinal disorder—Epirubicin—ovarian cancer	5.99e-05	0.000362	CcSEcCtD
Naproxen—Pain—Docetaxel—ovarian cancer	5.99e-05	0.000361	CcSEcCtD
Naproxen—Constipation—Docetaxel—ovarian cancer	5.99e-05	0.000361	CcSEcCtD
Naproxen—Chills—Epirubicin—ovarian cancer	5.96e-05	0.00036	CcSEcCtD
Naproxen—Arrhythmia—Epirubicin—ovarian cancer	5.94e-05	0.000358	CcSEcCtD
Naproxen—Visual impairment—Doxorubicin—ovarian cancer	5.93e-05	0.000358	CcSEcCtD
Naproxen—Asthenia—Paclitaxel—ovarian cancer	5.92e-05	0.000358	CcSEcCtD
Naproxen—Alopecia—Epirubicin—ovarian cancer	5.87e-05	0.000355	CcSEcCtD
Naproxen—Pruritus—Paclitaxel—ovarian cancer	5.84e-05	0.000353	CcSEcCtD
Naproxen—Mental disorder—Epirubicin—ovarian cancer	5.82e-05	0.000352	CcSEcCtD
Naproxen—Erythema multiforme—Doxorubicin—ovarian cancer	5.81e-05	0.000351	CcSEcCtD
Naproxen—Malnutrition—Epirubicin—ovarian cancer	5.78e-05	0.000349	CcSEcCtD
Naproxen—Erythema—Epirubicin—ovarian cancer	5.78e-05	0.000349	CcSEcCtD
Naproxen—Feeling abnormal—Docetaxel—ovarian cancer	5.77e-05	0.000348	CcSEcCtD
Naproxen—Eye disorder—Doxorubicin—ovarian cancer	5.75e-05	0.000347	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—ovarian cancer	5.73e-05	0.000346	CcSEcCtD
Naproxen—Gastrointestinal pain—Docetaxel—ovarian cancer	5.72e-05	0.000346	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—ovarian cancer	5.71e-05	0.000345	CcSEcCtD
Naproxen—Flatulence—Epirubicin—ovarian cancer	5.7e-05	0.000344	CcSEcCtD
Naproxen—Tension—Epirubicin—ovarian cancer	5.68e-05	0.000343	CcSEcCtD
Naproxen—Diarrhoea—Paclitaxel—ovarian cancer	5.65e-05	0.000341	CcSEcCtD
Naproxen—Nervousness—Epirubicin—ovarian cancer	5.62e-05	0.000339	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—ovarian cancer	5.58e-05	0.000337	CcSEcCtD
Naproxen—Muscle spasms—Epirubicin—ovarian cancer	5.56e-05	0.000336	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—ovarian cancer	5.55e-05	0.000335	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—ovarian cancer	5.54e-05	0.000335	CcSEcCtD
Naproxen—Body temperature increased—Docetaxel—ovarian cancer	5.53e-05	0.000334	CcSEcCtD
Naproxen—Abdominal pain—Docetaxel—ovarian cancer	5.53e-05	0.000334	CcSEcCtD
Naproxen—Chills—Doxorubicin—ovarian cancer	5.52e-05	0.000333	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—ovarian cancer	5.49e-05	0.000332	CcSEcCtD
Naproxen—Dizziness—Paclitaxel—ovarian cancer	5.46e-05	0.00033	CcSEcCtD
Naproxen—Vision blurred—Epirubicin—ovarian cancer	5.45e-05	0.000329	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—ovarian cancer	5.43e-05	0.000328	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—ovarian cancer	5.39e-05	0.000325	CcSEcCtD
Naproxen—Ill-defined disorder—Epirubicin—ovarian cancer	5.37e-05	0.000324	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—ovarian cancer	5.35e-05	0.000323	CcSEcCtD
Naproxen—Erythema—Doxorubicin—ovarian cancer	5.35e-05	0.000323	CcSEcCtD
Naproxen—Anaemia—Epirubicin—ovarian cancer	5.35e-05	0.000323	CcSEcCtD
Naproxen—Flatulence—Doxorubicin—ovarian cancer	5.27e-05	0.000318	CcSEcCtD
Naproxen—Tension—Doxorubicin—ovarian cancer	5.25e-05	0.000317	CcSEcCtD
Naproxen—Vomiting—Paclitaxel—ovarian cancer	5.25e-05	0.000317	CcSEcCtD
Naproxen—Malaise—Epirubicin—ovarian cancer	5.22e-05	0.000315	CcSEcCtD
Naproxen—Rash—Paclitaxel—ovarian cancer	5.21e-05	0.000314	CcSEcCtD
Naproxen—Dermatitis—Paclitaxel—ovarian cancer	5.2e-05	0.000314	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—ovarian cancer	5.2e-05	0.000314	CcSEcCtD
Naproxen—Vertigo—Epirubicin—ovarian cancer	5.2e-05	0.000314	CcSEcCtD
Naproxen—Syncope—Epirubicin—ovarian cancer	5.19e-05	0.000313	CcSEcCtD
Naproxen—Leukopenia—Epirubicin—ovarian cancer	5.18e-05	0.000313	CcSEcCtD
Naproxen—Headache—Paclitaxel—ovarian cancer	5.17e-05	0.000312	CcSEcCtD
Naproxen—Hypersensitivity—Docetaxel—ovarian cancer	5.16e-05	0.000311	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—ovarian cancer	5.15e-05	0.000311	CcSEcCtD
Naproxen—Palpitations—Epirubicin—ovarian cancer	5.11e-05	0.000309	CcSEcCtD
Naproxen—Loss of consciousness—Epirubicin—ovarian cancer	5.08e-05	0.000307	CcSEcCtD
Naproxen—Cough—Epirubicin—ovarian cancer	5.05e-05	0.000305	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—ovarian cancer	5.04e-05	0.000305	CcSEcCtD
Naproxen—Asthenia—Docetaxel—ovarian cancer	5.02e-05	0.000303	CcSEcCtD
Naproxen—Convulsion—Epirubicin—ovarian cancer	5.01e-05	0.000303	CcSEcCtD
Naproxen—Hypertension—Epirubicin—ovarian cancer	4.99e-05	0.000302	CcSEcCtD
Naproxen—Ill-defined disorder—Doxorubicin—ovarian cancer	4.97e-05	0.0003	CcSEcCtD
Naproxen—Pruritus—Docetaxel—ovarian cancer	4.95e-05	0.000299	CcSEcCtD
Naproxen—Anaemia—Doxorubicin—ovarian cancer	4.95e-05	0.000299	CcSEcCtD
Naproxen—Chest pain—Epirubicin—ovarian cancer	4.92e-05	0.000297	CcSEcCtD
Naproxen—Arthralgia—Epirubicin—ovarian cancer	4.92e-05	0.000297	CcSEcCtD
Naproxen—Myalgia—Epirubicin—ovarian cancer	4.92e-05	0.000297	CcSEcCtD
Naproxen—Anxiety—Epirubicin—ovarian cancer	4.91e-05	0.000296	CcSEcCtD
Naproxen—Nausea—Paclitaxel—ovarian cancer	4.9e-05	0.000296	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	4.89e-05	0.000295	CcSEcCtD
Naproxen—Discomfort—Epirubicin—ovarian cancer	4.87e-05	0.000294	CcSEcCtD
Naproxen—Malaise—Doxorubicin—ovarian cancer	4.83e-05	0.000291	CcSEcCtD
Naproxen—Dry mouth—Epirubicin—ovarian cancer	4.82e-05	0.000291	CcSEcCtD
Naproxen—Vertigo—Doxorubicin—ovarian cancer	4.81e-05	0.00029	CcSEcCtD
Naproxen—Syncope—Doxorubicin—ovarian cancer	4.8e-05	0.00029	CcSEcCtD
Naproxen—Leukopenia—Doxorubicin—ovarian cancer	4.79e-05	0.000289	CcSEcCtD
Naproxen—Diarrhoea—Docetaxel—ovarian cancer	4.79e-05	0.000289	CcSEcCtD
Naproxen—Confusional state—Epirubicin—ovarian cancer	4.76e-05	0.000287	CcSEcCtD
Naproxen—Palpitations—Doxorubicin—ovarian cancer	4.73e-05	0.000286	CcSEcCtD
Naproxen—Anaphylactic shock—Epirubicin—ovarian cancer	4.72e-05	0.000285	CcSEcCtD
Naproxen—Oedema—Epirubicin—ovarian cancer	4.72e-05	0.000285	CcSEcCtD
Naproxen—Loss of consciousness—Doxorubicin—ovarian cancer	4.7e-05	0.000284	CcSEcCtD
Naproxen—Infection—Epirubicin—ovarian cancer	4.69e-05	0.000283	CcSEcCtD
Naproxen—Cough—Doxorubicin—ovarian cancer	4.67e-05	0.000282	CcSEcCtD
Naproxen—Shock—Epirubicin—ovarian cancer	4.64e-05	0.00028	CcSEcCtD
Naproxen—Convulsion—Doxorubicin—ovarian cancer	4.64e-05	0.00028	CcSEcCtD
Naproxen—Nervous system disorder—Epirubicin—ovarian cancer	4.63e-05	0.00028	CcSEcCtD
Naproxen—Dizziness—Docetaxel—ovarian cancer	4.63e-05	0.00028	CcSEcCtD
Naproxen—Thrombocytopenia—Epirubicin—ovarian cancer	4.62e-05	0.000279	CcSEcCtD
Naproxen—Hypertension—Doxorubicin—ovarian cancer	4.62e-05	0.000279	CcSEcCtD
Naproxen—Tachycardia—Epirubicin—ovarian cancer	4.61e-05	0.000278	CcSEcCtD
Naproxen—Skin disorder—Epirubicin—ovarian cancer	4.59e-05	0.000277	CcSEcCtD
Naproxen—Hyperhidrosis—Epirubicin—ovarian cancer	4.56e-05	0.000276	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—ovarian cancer	4.56e-05	0.000275	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—ovarian cancer	4.56e-05	0.000275	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—ovarian cancer	4.56e-05	0.000275	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—ovarian cancer	4.54e-05	0.000274	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	4.53e-05	0.000273	CcSEcCtD
Naproxen—Discomfort—Doxorubicin—ovarian cancer	4.5e-05	0.000272	CcSEcCtD
Naproxen—Anorexia—Epirubicin—ovarian cancer	4.5e-05	0.000272	CcSEcCtD
Naproxen—Dry mouth—Doxorubicin—ovarian cancer	4.46e-05	0.000269	CcSEcCtD
Naproxen—Vomiting—Docetaxel—ovarian cancer	4.45e-05	0.000269	CcSEcCtD
Naproxen—Rash—Docetaxel—ovarian cancer	4.41e-05	0.000267	CcSEcCtD
Naproxen—Hypotension—Epirubicin—ovarian cancer	4.41e-05	0.000266	CcSEcCtD
Naproxen—Dermatitis—Docetaxel—ovarian cancer	4.41e-05	0.000266	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—ovarian cancer	4.4e-05	0.000266	CcSEcCtD
Naproxen—Headache—Docetaxel—ovarian cancer	4.38e-05	0.000265	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—ovarian cancer	4.37e-05	0.000264	CcSEcCtD
Naproxen—Oedema—Doxorubicin—ovarian cancer	4.37e-05	0.000264	CcSEcCtD
Naproxen—Infection—Doxorubicin—ovarian cancer	4.34e-05	0.000262	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Epirubicin—ovarian cancer	4.3e-05	0.00026	CcSEcCtD
Naproxen—Shock—Doxorubicin—ovarian cancer	4.3e-05	0.00026	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—ovarian cancer	4.28e-05	0.000259	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—ovarian cancer	4.28e-05	0.000258	CcSEcCtD
Naproxen—Insomnia—Epirubicin—ovarian cancer	4.27e-05	0.000258	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—ovarian cancer	4.26e-05	0.000257	CcSEcCtD
Naproxen—Skin disorder—Doxorubicin—ovarian cancer	4.24e-05	0.000256	CcSEcCtD
Naproxen—Paraesthesia—Epirubicin—ovarian cancer	4.24e-05	0.000256	CcSEcCtD
Naproxen—Hyperhidrosis—Doxorubicin—ovarian cancer	4.22e-05	0.000255	CcSEcCtD
Naproxen—Dyspnoea—Epirubicin—ovarian cancer	4.21e-05	0.000254	CcSEcCtD
Naproxen—Somnolence—Epirubicin—ovarian cancer	4.2e-05	0.000253	CcSEcCtD
Naproxen—Anorexia—Doxorubicin—ovarian cancer	4.16e-05	0.000251	CcSEcCtD
Naproxen—Nausea—Docetaxel—ovarian cancer	4.16e-05	0.000251	CcSEcCtD
Naproxen—Dyspepsia—Epirubicin—ovarian cancer	4.16e-05	0.000251	CcSEcCtD
Naproxen—Decreased appetite—Epirubicin—ovarian cancer	4.1e-05	0.000248	CcSEcCtD
Naproxen—Hypotension—Doxorubicin—ovarian cancer	4.08e-05	0.000246	CcSEcCtD
Naproxen—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.08e-05	0.000246	CcSEcCtD
Naproxen—Fatigue—Epirubicin—ovarian cancer	4.07e-05	0.000246	CcSEcCtD
Naproxen—Pain—Epirubicin—ovarian cancer	4.04e-05	0.000244	CcSEcCtD
Naproxen—Constipation—Epirubicin—ovarian cancer	4.04e-05	0.000244	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.98e-05	0.00024	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—ovarian cancer	3.95e-05	0.000239	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—ovarian cancer	3.92e-05	0.000237	CcSEcCtD
Naproxen—Dyspnoea—Doxorubicin—ovarian cancer	3.89e-05	0.000235	CcSEcCtD
Naproxen—Feeling abnormal—Epirubicin—ovarian cancer	3.89e-05	0.000235	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—ovarian cancer	3.88e-05	0.000235	CcSEcCtD
Naproxen—Gastrointestinal pain—Epirubicin—ovarian cancer	3.86e-05	0.000233	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—ovarian cancer	3.85e-05	0.000232	CcSEcCtD
Naproxen—Decreased appetite—Doxorubicin—ovarian cancer	3.8e-05	0.000229	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3.77e-05	0.000228	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—ovarian cancer	3.77e-05	0.000227	CcSEcCtD
Naproxen—Urticaria—Epirubicin—ovarian cancer	3.75e-05	0.000226	CcSEcCtD
Naproxen—Pain—Doxorubicin—ovarian cancer	3.74e-05	0.000226	CcSEcCtD
Naproxen—Constipation—Doxorubicin—ovarian cancer	3.74e-05	0.000226	CcSEcCtD
Naproxen—Body temperature increased—Epirubicin—ovarian cancer	3.73e-05	0.000225	CcSEcCtD
Naproxen—Abdominal pain—Epirubicin—ovarian cancer	3.73e-05	0.000225	CcSEcCtD
Naproxen—Feeling abnormal—Doxorubicin—ovarian cancer	3.6e-05	0.000217	CcSEcCtD
Naproxen—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.57e-05	0.000216	CcSEcCtD
Naproxen—Hypersensitivity—Epirubicin—ovarian cancer	3.48e-05	0.00021	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—ovarian cancer	3.47e-05	0.00021	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—ovarian cancer	3.45e-05	0.000209	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—ovarian cancer	3.45e-05	0.000209	CcSEcCtD
Naproxen—Asthenia—Epirubicin—ovarian cancer	3.39e-05	0.000205	CcSEcCtD
Naproxen—Pruritus—Epirubicin—ovarian cancer	3.34e-05	0.000202	CcSEcCtD
Naproxen—Diarrhoea—Epirubicin—ovarian cancer	3.23e-05	0.000195	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—ovarian cancer	3.22e-05	0.000194	CcSEcCtD
Naproxen—Asthenia—Doxorubicin—ovarian cancer	3.13e-05	0.000189	CcSEcCtD
Naproxen—Dizziness—Epirubicin—ovarian cancer	3.12e-05	0.000189	CcSEcCtD
Naproxen—Pruritus—Doxorubicin—ovarian cancer	3.09e-05	0.000187	CcSEcCtD
Naproxen—Vomiting—Epirubicin—ovarian cancer	3e-05	0.000181	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—ovarian cancer	2.99e-05	0.00018	CcSEcCtD
Naproxen—Rash—Epirubicin—ovarian cancer	2.98e-05	0.00018	CcSEcCtD
Naproxen—Dermatitis—Epirubicin—ovarian cancer	2.97e-05	0.00018	CcSEcCtD
Naproxen—Headache—Epirubicin—ovarian cancer	2.96e-05	0.000179	CcSEcCtD
Naproxen—Dizziness—Doxorubicin—ovarian cancer	2.89e-05	0.000174	CcSEcCtD
Naproxen—Nausea—Epirubicin—ovarian cancer	2.8e-05	0.000169	CcSEcCtD
Naproxen—Vomiting—Doxorubicin—ovarian cancer	2.78e-05	0.000168	CcSEcCtD
Naproxen—Rash—Doxorubicin—ovarian cancer	2.75e-05	0.000166	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—ovarian cancer	2.75e-05	0.000166	CcSEcCtD
Naproxen—Headache—Doxorubicin—ovarian cancer	2.74e-05	0.000165	CcSEcCtD
Naproxen—Nausea—Doxorubicin—ovarian cancer	2.59e-05	0.000157	CcSEcCtD
Naproxen—SLCO1A2—Metabolism—PPP2R1A—ovarian cancer	1.15e-05	0.000427	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.14e-05	0.000426	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.14e-05	0.000425	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.12e-05	0.00042	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—APC—ovarian cancer	1.12e-05	0.000418	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CG—ovarian cancer	1.12e-05	0.000418	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.11e-05	0.000414	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.09e-05	0.000406	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CTNNB1—ovarian cancer	1.09e-05	0.000406	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—FASN—ovarian cancer	1.08e-05	0.000403	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	1.07e-05	0.0004	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PPP2R1A—ovarian cancer	1.07e-05	0.000399	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ABCB1—ovarian cancer	1.06e-05	0.000397	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—SLC5A5—ovarian cancer	1.06e-05	0.000396	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTEN—ovarian cancer	1.06e-05	0.000395	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—YAP1—ovarian cancer	1.05e-05	0.000392	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—TYMS—ovarian cancer	1.04e-05	0.00039	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.04e-05	0.000388	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPP1CC—ovarian cancer	1.04e-05	0.000387	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—BRIP1—ovarian cancer	1.04e-05	0.000387	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CB—ovarian cancer	1.03e-05	0.000383	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—SLC2A1—ovarian cancer	1.02e-05	0.000382	CbGpPWpGaD
Naproxen—PTGS2—Disease—FASN—ovarian cancer	1.02e-05	0.000382	CbGpPWpGaD
Naproxen—PTGS2—Disease—PARP1—ovarian cancer	1.02e-05	0.00038	CbGpPWpGaD
Naproxen—ALB—Hemostasis—CAV1—ovarian cancer	1.01e-05	0.000378	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYTB—ovarian cancer	1.01e-05	0.000378	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	1.01e-05	0.000378	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1e-05	0.000374	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ABCB1—ovarian cancer	9.92e-06	0.00037	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	9.91e-06	0.00037	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CD—ovarian cancer	9.85e-06	0.000368	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP1B1—ovarian cancer	9.82e-06	0.000367	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—TYMS—ovarian cancer	9.75e-06	0.000364	CbGpPWpGaD
Naproxen—PTGS2—Disease—SLC2A1—ovarian cancer	9.71e-06	0.000362	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CAV1—ovarian cancer	9.66e-06	0.000361	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	9.65e-06	0.00036	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	9.5e-06	0.000355	CbGpPWpGaD
Naproxen—AKR1C3—Disease—STAT3—ovarian cancer	9.47e-06	0.000354	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NRAS—ovarian cancer	9.45e-06	0.000353	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	9.29e-06	0.000347	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CG—ovarian cancer	9.24e-06	0.000345	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	9.23e-06	0.000345	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.14e-06	0.000341	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MAPK3—ovarian cancer	9.05e-06	0.000338	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTEN—ovarian cancer	8.87e-06	0.000331	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—BRIP1—ovarian cancer	8.86e-06	0.000331	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPP1CC—ovarian cancer	8.86e-06	0.000331	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CG—ovarian cancer	8.8e-06	0.000329	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MYC—ovarian cancer	8.8e-06	0.000329	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PPP2R1A—ovarian cancer	8.71e-06	0.000325	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ERBB2—ovarian cancer	8.7e-06	0.000325	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.67e-06	0.000324	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MAPK1—ovarian cancer	8.61e-06	0.000321	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EGFR—ovarian cancer	8.61e-06	0.000321	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MTOR—ovarian cancer	8.58e-06	0.00032	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CB—ovarian cancer	8.58e-06	0.00032	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—FASN—ovarian cancer	8.56e-06	0.00032	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—YAP1—ovarian cancer	8.55e-06	0.000319	CbGpPWpGaD
Naproxen—ALB—Metabolism—YAP1—ovarian cancer	8.5e-06	0.000317	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.46e-06	0.000316	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—SLC5A5—ovarian cancer	8.42e-06	0.000314	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CAV1—ovarian cancer	8.42e-06	0.000314	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.41e-06	0.000314	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	8.37e-06	0.000312	CbGpPWpGaD
Naproxen—PTGS2—Disease—PPP2R1A—ovarian cancer	8.26e-06	0.000308	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL8—ovarian cancer	8.25e-06	0.000308	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—SLC2A1—ovarian cancer	8.13e-06	0.000304	CbGpPWpGaD
Naproxen—AKR1C3—Disease—KRAS—ovarian cancer	8.13e-06	0.000304	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CD—ovarian cancer	8.12e-06	0.000303	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ABCB1—ovarian cancer	8.09e-06	0.000302	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CDKN1B—ovarian cancer	8.06e-06	0.000301	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	8.04e-06	0.0003	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.97e-06	0.000297	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—TYMS—ovarian cancer	7.95e-06	0.000297	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CASP3—ovarian cancer	7.9e-06	0.000295	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL2—ovarian cancer	7.88e-06	0.000294	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CAV1—ovarian cancer	7.85e-06	0.000293	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP1B1—ovarian cancer	7.8e-06	0.000291	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CD—ovarian cancer	7.74e-06	0.000289	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCND1—ovarian cancer	7.68e-06	0.000287	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CG—ovarian cancer	7.67e-06	0.000286	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CTNNB1—ovarian cancer	7.61e-06	0.000284	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	7.56e-06	0.000282	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PIK3CA—ovarian cancer	7.47e-06	0.000279	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—ovarian cancer	7.46e-06	0.000278	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.44e-06	0.000277	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTEN—ovarian cancer	7.42e-06	0.000277	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.39e-06	0.000276	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CG—ovarian cancer	7.15e-06	0.000267	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CB—ovarian cancer	7.08e-06	0.000264	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—FASN—ovarian cancer	6.97e-06	0.00026	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—YAP1—ovarian cancer	6.96e-06	0.00026	CbGpPWpGaD
Naproxen—ALB—Metabolism—FASN—ovarian cancer	6.93e-06	0.000259	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PPP2R1A—ovarian cancer	6.92e-06	0.000258	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HRAS—ovarian cancer	6.91e-06	0.000258	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.88e-06	0.000257	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.88e-06	0.000257	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SLC5A5—ovarian cancer	6.85e-06	0.000256	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	6.84e-06	0.000255	CbGpPWpGaD
Naproxen—ALB—Metabolism—SLC5A5—ovarian cancer	6.81e-06	0.000254	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CB—ovarian cancer	6.75e-06	0.000252	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CD—ovarian cancer	6.74e-06	0.000251	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—ovarian cancer	6.7e-06	0.00025	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—ovarian cancer	6.63e-06	0.000248	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SLC2A1—ovarian cancer	6.62e-06	0.000247	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NRAS—ovarian cancer	6.62e-06	0.000247	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IL6—ovarian cancer	6.62e-06	0.000247	CbGpPWpGaD
Naproxen—ALB—Metabolism—SLC2A1—ovarian cancer	6.58e-06	0.000246	CbGpPWpGaD
Naproxen—PTGS2—Disease—TERT—ovarian cancer	6.56e-06	0.000245	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2—ovarian cancer	6.5e-06	0.000243	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.48e-06	0.000242	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.46e-06	0.000241	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.44e-06	0.00024	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ABCB1—ovarian cancer	6.42e-06	0.00024	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CAV1—ovarian cancer	6.4e-06	0.000239	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP1B1—ovarian cancer	6.35e-06	0.000237	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK3—ovarian cancer	6.34e-06	0.000237	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP1B1—ovarian cancer	6.31e-06	0.000235	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—TYMS—ovarian cancer	6.31e-06	0.000235	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CD—ovarian cancer	6.29e-06	0.000235	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CA—ovarian cancer	6.26e-06	0.000234	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—ovarian cancer	6.16e-06	0.00023	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.12e-06	0.000228	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—ovarian cancer	6.1e-06	0.000228	CbGpPWpGaD
Naproxen—PTGS2—Disease—CAV1—ovarian cancer	6.07e-06	0.000226	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6.05e-06	0.000226	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK1—ovarian cancer	6.03e-06	0.000225	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—ovarian cancer	6.03e-06	0.000225	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—YAP1—ovarian cancer	5.94e-06	0.000222	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	5.88e-06	0.00022	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CB—ovarian cancer	5.87e-06	0.000219	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CG—ovarian cancer	5.83e-06	0.000218	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—ovarian cancer	5.83e-06	0.000218	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6ST—ovarian cancer	5.75e-06	0.000215	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—ovarian cancer	5.7e-06	0.000213	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—FASN—ovarian cancer	5.67e-06	0.000212	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	5.63e-06	0.00021	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.6e-06	0.000209	CbGpPWpGaD
Naproxen—ALB—Metabolism—PPP2R1A—ovarian cancer	5.6e-06	0.000209	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC5A5—ovarian cancer	5.58e-06	0.000208	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.57e-06	0.000208	CbGpPWpGaD
Naproxen—PTGS2—Disease—APC—ovarian cancer	5.53e-06	0.000206	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—ovarian cancer	5.52e-06	0.000206	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CB—ovarian cancer	5.48e-06	0.000205	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NRAS—ovarian cancer	5.46e-06	0.000204	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC2A1—ovarian cancer	5.39e-06	0.000201	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.27e-06	0.000197	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—ovarian cancer	5.23e-06	0.000195	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK3—ovarian cancer	5.23e-06	0.000195	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ABCB1—ovarian cancer	5.23e-06	0.000195	CbGpPWpGaD
Naproxen—ALB—Metabolism—ABCB1—ovarian cancer	5.2e-06	0.000194	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.17e-06	0.000193	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP1B1—ovarian cancer	5.16e-06	0.000193	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TYMS—ovarian cancer	5.13e-06	0.000192	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CD—ovarian cancer	5.13e-06	0.000191	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—ovarian cancer	5.11e-06	0.000191	CbGpPWpGaD
Naproxen—ALB—Metabolism—TYMS—ovarian cancer	5.1e-06	0.00019	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CAV1—ovarian cancer	5.08e-06	0.00019	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—ovarian cancer	5.08e-06	0.000189	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—ovarian cancer	5.06e-06	0.000189	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK1—ovarian cancer	4.97e-06	0.000186	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CD—ovarian cancer	4.86e-06	0.000181	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.86e-06	0.000181	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—FASN—ovarian cancer	4.85e-06	0.000181	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—ovarian cancer	4.84e-06	0.000181	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC5A5—ovarian cancer	4.77e-06	0.000178	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—ovarian cancer	4.74e-06	0.000177	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—ovarian cancer	4.7e-06	0.000175	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—ovarian cancer	4.63e-06	0.000173	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CG—ovarian cancer	4.63e-06	0.000173	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC2A1—ovarian cancer	4.6e-06	0.000172	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	4.58e-06	0.000171	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.56e-06	0.00017	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.51e-06	0.000168	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CB—ovarian cancer	4.47e-06	0.000167	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP1B1—ovarian cancer	4.41e-06	0.000165	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—ovarian cancer	4.31e-06	0.000161	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB2—ovarian cancer	4.29e-06	0.00016	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—ovarian cancer	4.27e-06	0.00016	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ABCB1—ovarian cancer	4.25e-06	0.000159	CbGpPWpGaD
Naproxen—PTGS2—Disease—MTOR—ovarian cancer	4.24e-06	0.000158	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CB—ovarian cancer	4.24e-06	0.000158	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TYMS—ovarian cancer	4.18e-06	0.000156	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—ovarian cancer	4.17e-06	0.000156	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CAV1—ovarian cancer	4.14e-06	0.000154	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—ovarian cancer	4.11e-06	0.000153	CbGpPWpGaD
Naproxen—ALB—Metabolism—CAV1—ovarian cancer	4.11e-06	0.000153	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CD—ovarian cancer	4.07e-06	0.000152	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—ovarian cancer	3.99e-06	0.000149	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1B—ovarian cancer	3.97e-06	0.000148	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.95e-06	0.000147	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.93e-06	0.000147	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	3.91e-06	0.000146	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.89e-06	0.000145	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—ovarian cancer	3.86e-06	0.000144	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CG—ovarian cancer	3.77e-06	0.000141	CbGpPWpGaD
Naproxen—PTGS2—Disease—CTNNB1—ovarian cancer	3.76e-06	0.00014	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CG—ovarian cancer	3.75e-06	0.00014	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—ovarian cancer	3.66e-06	0.000137	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCB1—ovarian cancer	3.63e-06	0.000136	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—ovarian cancer	3.58e-06	0.000134	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TYMS—ovarian cancer	3.57e-06	0.000133	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CB—ovarian cancer	3.55e-06	0.000132	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—ovarian cancer	3.52e-06	0.000132	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CAV1—ovarian cancer	3.37e-06	0.000126	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—ovarian cancer	3.36e-06	0.000125	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—ovarian cancer	3.34e-06	0.000125	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CD—ovarian cancer	3.31e-06	0.000124	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CD—ovarian cancer	3.29e-06	0.000123	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—ovarian cancer	3.27e-06	0.000122	CbGpPWpGaD
Naproxen—PTGS2—Disease—NRAS—ovarian cancer	3.27e-06	0.000122	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.22e-06	0.00012	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK3—ovarian cancer	3.13e-06	0.000117	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CG—ovarian cancer	3.07e-06	0.000114	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—ovarian cancer	3.07e-06	0.000114	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—ovarian cancer	3.04e-06	0.000114	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK1—ovarian cancer	2.98e-06	0.000111	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—ovarian cancer	2.98e-06	0.000111	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—ovarian cancer	2.93e-06	0.000109	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CB—ovarian cancer	2.89e-06	0.000108	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CAV1—ovarian cancer	2.88e-06	0.000107	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CB—ovarian cancer	2.87e-06	0.000107	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—ovarian cancer	2.81e-06	0.000105	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.75e-06	0.000103	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—ovarian cancer	2.73e-06	0.000102	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—ovarian cancer	2.72e-06	0.000102	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CD—ovarian cancer	2.7e-06	0.000101	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.62e-06	9.78e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—ovarian cancer	2.58e-06	9.64e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—ovarian cancer	2.49e-06	9.31e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—ovarian cancer	2.48e-06	9.25e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—ovarian cancer	2.39e-06	8.92e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CB—ovarian cancer	2.35e-06	8.77e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CD—ovarian cancer	2.3e-06	8.59e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—ovarian cancer	2.29e-06	8.53e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—ovarian cancer	2.23e-06	8.3e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—ovarian cancer	2.16e-06	8.07e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—ovarian cancer	2.11e-06	7.87e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—ovarian cancer	2.03e-06	7.58e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CB—ovarian cancer	2.01e-06	7.49e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—ovarian cancer	1.77e-06	6.59e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.76e-06	6.57e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—ovarian cancer	1.75e-06	6.53e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—ovarian cancer	1.73e-06	6.47e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—ovarian cancer	1.44e-06	5.36e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.43e-06	5.34e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—ovarian cancer	1.43e-06	5.33e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.22e-06	4.57e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—ovarian cancer	1.17e-06	4.37e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—ovarian cancer	1e-06	3.73e-05	CbGpPWpGaD
